Skip to main content
Home > BioCentury on BioBusiness > Cover Story

Chronological Index of : Cover Story

 Current Issue
  • Figure: London vs. Europe

    None shall pass London vs. Europe The BioCentury Europe index is back to where it started last September, after gaining 18% in 4Q15 and then declining 11% last quarter. Seventeen of 19 continental European …

    Published on 4/4/2016
  • Figure: Price-to-earnings: BT vs. RX

    None shall pass Price-to-earnings: BT vs. RX Biotech's average P/E ended 1Q at 20.8, down 14% from 4Q15 and 17% from a year ago. Two companies — rare disease play Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) and …

    Published on 4/4/2016
  • Figure: Results by market cap

    None shall pass Results by market cap All market cap segments fell more than 12% in 1Q. Companies valued at $5 billion or more fell by a median of 16%, led by a 74% decline in the share price of Valeant …

    Published on 4/4/2016
  • Table: 1Q approvals

    None shall pass 1Q approvals Selected 1Q approvals. Company Approval Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) Japan approves Kanuma sebelipase alfa to treat lysosomal acid lipase deficiency (LAL-D) Amgen …

    Published on 4/4/2016
  • Table: Index performance

    None shall pass Index performance Index 1Q16 DJIA 1% S&P 500 1% NASDAQ Composite -3% BioCentury London -7% NYSE Arca Pharmaceutical -9% BioCentury Europe -11% NYSE Arca Biotechnology -22% NASDAQ …

    Published on 4/4/2016
  • Table: Restructuring watch

    None shall pass Restructuring watch At least nine companies reported workforce reductions in the first quarter compared to at least five in the same period last year. Table below is sorted by date ascending. All …

    Published on 4/4/2016
  • Editors' Commentary: Save the baby

    Why biopharma should fight to create a true value-based experiment at CMS, not kill it

    CMS should not go forward with its flawed value-based payment experiment. But the stakeholders need to fix it, not to kill it outright.

    Published on 3/28/2016
  • Korea rising

    How the Korean biopharma landscape is evolving

    With the success of Hanmi and an infusion of government money, Korea's biopharma industry is building a virtuous circle for innovation.

    Published on 3/21/2016
  • Box: Baby steps

    Korea rising Baby steps Several Korean biotechs told BioCentury that despite an increase in development of innovator products, the country is lacking in the expertise needed to execute global clinical development …

    Published on 3/21/2016
  • Box: Korea comps

    Korea rising Korea comps B. Christopher Kim, managing partner at Korea-Seoul Life Sciences Fund, told BioCentury the firm did not start out with a Korea focus. The fund closed at W75 billion ($67.5 million) in …

    Published on 3/21/2016
  • Box: Korea opens up

    Korea rising Korea opens up Much like in the U.S. and Europe, established Korean biopharma companies have started to work with local universities and small biotechs to identify and invest in innovative …

    Published on 3/21/2016
  • Figure: R&D growth

    Korea rising R&D growth From 2009 to 2013, R&D spending by the Korean pharmaceutical industry has increased. While absolute spending still pales in comparison to larger countries, Korea's R&D outlays have grown at…

    Published on 3/21/2016
  • Table: Korea funds

    Korea rising Korea funds The South Korean government has launched four funding initiatives totalling $2 billion to help spur R&D for innovative drugs and promote global expansion of the nation's biotech industry. …

    Published on 3/21/2016
  • Value demonstration

    Hurdles CMS must clear to test value-based schemes for Part B drugs

    Oncologists, hospitals, drug companies and Republicans are trying to kill CMS's proposal to test value-based schemes for Part B drugs.

    Published on 3/14/2016
  • Table: Part B targets

    Value demonstration Part B targets CMS is proposing a nationwide, mandatory "demonstration project" to assess whether and how various changes in Part B drug reimbursement policies would affect costs and clinical …

    Published on 3/14/2016
  • Table: Putting value to the test

    Value demonstration Putting value to the test CMS is proposing a nationwide controlled experiment to test alternative systems for paying for drugs provided under the Part B Medicare benefit, which includes drugs …

    Published on 3/14/2016
  • Getting combinations right

    How FDA may adapt to review products combining drugs, devices, biologics

    FDA is working on changes -- some small, some radical -- to improve regulation of products combining drugs, devices and biologics.

    Published on 3/7/2016
  • Infectious enthusiasm

    How oncolytic viruses are coming of age in cancer immunotherapy combinations

    Checkpoint agents could give oncolytic viruses an efficacy boost as the field learns how to make viruses deliver their own potentiators.

    Published on 2/29/2016
  • Box: Oncolytic duos and Dx

    Infectious enthusiasm Oncolytic duos and Dx Several companies are looking for therapeutic combinations that change how oncolytic viruses interact with cancer cells. At least two companies, Oncolys BioPharma Inc. …

    Published on 2/29/2016
  • Figure: Oncolytic pipeline

    Infectious enthusiasm Oncolytic pipeline At least 19 oncolytic viruses are in clinical development. For products in development for multiple indications, the status of the lead indication is shown. Many viruses …

    Published on 2/29/2016
  • Figure: The BioVex effect

    Infectious enthusiasm The BioVex effect In the last five years, oncolytic virus companies raised $360.2 million via equity offerings, topping the $321.5 million raised in 2000-10. The catalyst of renewed attention…

    Published on 2/29/2016
  • Figure: Two-pronged attack

    Infectious enthusiasm Two-pronged attack Oncolytic viruses can stimulate both direct and indirect killing of cancer cells, as illustrated by Imlygic talimogene laherparepvec (T-Vec) from Amgen Inc. (NASDAQ:AMGN). …

    Published on 2/29/2016
  • Box: IBD intuition

    Extrapolating mAbs IBD intuition FDA's Arthritis Advisory Committee may have overwhelmingly backed Celltrion Inc.'s biosimilar of Remicade infliximab, but comments by GI doctors on the panel and from patients …

    Published on 2/22/2016
  • Box: mAb about MOA

    Extrapolating mAbs mAb about MOA A complicating factor in the development of biosimilar mAbs is that monoclonals can exert their efficacy via multiple mechanisms and the MOA can vary depending on the disease. …

    Published on 2/22/2016
  • Figure: ADCC analysis

    Extrapolating mAbs ADCC analysis As antibody-dependent cell-mediated cytotoxicity is among the different mechanisms through which Remicade infliximab exerts its efficacy, Celltrion Inc. (KOSDAQ:068270) conducted …

    Published on 2/22/2016

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993